Michi Shinohara, MD
Dermatology · Seattle, WANPI 1750491650
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,680 of the $2,126 with a category attached, or 79.0%. Kyowa Kirin, Inc. accounts for 88.3% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $1,711, 6.9 times the $248 reported in 2022.
Across 6 payments — averaging $354.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$2K
- Seagen Inc.$248
Across 41 payments — averaging $6692.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Co., Ltd.$202K
- Kyowa Kirin Services Ltd$73K
What the payments were for
- Consulting fees$1,68079%
- Food & beverage$44621%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 4 | $1,878 |
| Seagen Inc. | 2 | $248 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- POTELIGEO$1,800
How this compares
$2,126 in reported general payments places this provider in the 65th percentile of 323 dermatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $80,311 |
| Bexarotene | 14 | $14,526 |
| Clobetasol Propionate | 53 | $1,517 |
| MethotrexateMethotrexate Sodium | 52 | $908 |
| Triamcinolone Acetonide | 50 | $662 |
| Gabapentin | 23 | $318 |
| Levothyroxine Sodium | 12 | $175 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Seattle
- Vivian ShiSeattle$971K
- James CollyerSeattle$115K
- Alison YoungSeattle$53K
- Paul NghiemSeattle$32K
- Andrew LinSeattle$19K
- John ScopettaSeattle$15K
- Tien NguyenSeattle$13K
- Paula ZookSeattle$12K
- Cory SimpsonSeattle$12K
- James HuSeattle$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.